Clinical efficacy of teicoplanin in the treatment of bloodstream infection caused by methicillin-resistant coagulase-negative staphylococci.

[1]  Zhixin Liang,et al.  The species distribution, antimicrobial resistance and risk factors for poor outcome of coagulase-negative staphylococci bacteraemia in China , 2019, Antimicrobial Resistance & Infection Control.

[2]  M. Castanheira,et al.  Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010–2016): concomitant analysis of oritavancin in vitro activity , 2018, Journal of chemotherapy.

[3]  K. Hamed,et al.  Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015 , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  A. Delmer,et al.  Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration , 2017, Infectious diseases.

[5]  Y. Kaneko,et al.  Clinical Characteristics of Methicillin-resistant Coagulase-negative Staphylococcal Bacteremia in a Tertiary Hospital , 2017, Internal medicine.

[6]  H. Ikeuchi,et al.  Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  K. McConeghy,et al.  The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  D. Warren,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Livermore,et al.  Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. , 2008, The Journal of antimicrobial chemotherapy.

[10]  E. Giraud,et al.  Complete sequence of the floR-carrying multiresistance plasmid pAB5S9 from freshwater Aeromonas bestiarum. , 2008, The Journal of antimicrobial chemotherapy.

[11]  Margaret A Dudeck,et al.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. , 2008, American journal of infection control.

[12]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Bint,et al.  Susceptibility of staphylococci to teicoplanin and vancomycin. , 1996, The Journal of antimicrobial chemotherapy.

[14]  G. Archer,et al.  Antimicrobial susceptibility of coagulase-negative staphylococci , 1994, Antimicrobial Agents and Chemotherapy.

[15]  J. Pellegrin,et al.  In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients , 1990, Antimicrobial Agents and Chemotherapy.

[16]  H. Ikeuchi,et al.  High-dose regimen to achieve novel target trough concentration in teicoplanin. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[17]  H. Ikeuchi,et al.  Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.